MarketCap
Facebook
X
TelegramQuartalsbericht 2023-Q2
hinzugefügt 10.08.2023
Infinity Pharmaceuticals Betriebsaufwand 2011-2026 | INFI
Betriebsaufwand Jährlich Infinity Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 47.4 M | 46.9 M | 39.2 M | 41.4 M | 34 M | 42.4 M | 162 M | 236 M | 173 M | 128 M | 146 M | 131 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 236 M | 34 M | 102 M |
Betriebsaufwand Vierteljährlich Infinity Pharmaceuticals
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.7 M | 12.2 M | - | 11.6 M | 12.7 M | 13.1 M | - | 11.2 M | 11.8 M | 12 M | - | 9.34 M | 9.28 M | 10.9 M | - | 10.9 M | 10 M | 15.9 M | - | 8.82 M | 7.14 M | 9.52 M | 8.02 M | 13.8 M | 10.1 M | 10.5 M | 23.2 M | 19.9 M | 68.6 M | 50 M | 48.2 M | 47.5 M | 43.5 M | 97 M | 43.5 M | 52.9 M | 35.2 M | 41.3 M | 33.1 M | 34.2 M | 32.8 M | 27.7 M | 47.1 M | 27.8 M | 36.2 M | 35.4 M | 35.9 M | 34.9 M | 31.3 M | 29.2 M |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 97 M | 7.14 M | 26.8 M |
Betriebsaufwand anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
ACADIA Pharmaceuticals
ACAD
|
708 M | $ 22.57 | 0.04 % | $ 3.74 B |  USA |
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
Adverum Biotechnologies
ADVM
|
140 M | - | - | $ 86.2 M | USA |
 |
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | USA |
 |
Allakos
ALLK
|
196 M | - | - | $ 28.6 M | USA |
 |
Akebia Therapeutics
AKBA
|
173 M | $ 1.41 | -1.4 % | $ 363 M | USA |
 |
AlloVir
ALVR
|
46.2 M | - | 4.14 % | $ 49.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | USA |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B |  France |
 |
Applied Therapeutics
APLT
|
74.5 M | - | - | $ 8.42 M | USA |
 |
Aravive
ARAV
|
80 M | - | -13.39 % | $ 1.45 M | USA |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
BioNTech SE
BNTX
|
512 M | $ 91.98 | -0.11 % | $ 27.2 B | Germany |
 |
Aytu BioScience
AYTU
|
53.7 M | $ 2.56 | -3.76 % | $ 16.1 M | USA |
 |
AstraZeneca PLC
AZN
|
17.6 B | - | - | $ 96.9 B | Britain |
 |
Alterity Therapeutics Limited
ATHE
|
16.7 M | $ 3.85 | -1.39 % | $ 9.26 B |  Australia |
 |
AVROBIO
AVRO
|
71.7 M | - | 1083.1 % | $ 745 M | USA |
 |
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
216 M | $ 20.87 | 2.3 % | $ 976 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
31.7 M | - | -2.5 % | $ 5.88 M | USA |
 |
Aquestive Therapeutics
AQST
|
85.5 M | $ 4.17 | -0.24 % | $ 446 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M |  Israel |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Arcutis Biotherapeutics
ARQT
|
137 M | $ 24.57 | -0.16 % | $ 3.13 B | USA |
 |
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Aeterna Zentaris
AEZS
|
23 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
24.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | USA |
 |
CymaBay Therapeutics
CBAY
|
133 M | - | - | $ 3.45 B | USA |
 |
AIkido Pharma
AIKI
|
179 M | - | 1.93 % | $ 17.4 M | USA |
 |
Cabaletta Bio
CABA
|
172 M | $ 3.17 | 2.59 % | $ 319 M | USA |
 |
Codiak BioSciences
CDAK
|
92.5 M | - | -55.98 % | $ 2.15 M | USA |
 |
Aptose Biosciences
APTO
|
24.7 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Avid Bioservices
CDMO
|
26 M | - | - | $ 789 M | USA |
 |
Cidara Therapeutics
CDTX
|
177 M | - | - | $ 1.41 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
14 M | $ 2.93 | -4.87 % | $ 6.38 B | Israel |
 |
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | USA |
 |
Checkpoint Therapeutics
CKPT
|
56.2 M | - | - | $ 169 M | USA |
 |
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | Germany |
 |
Celldex Therapeutics
CLDX
|
58.1 M | $ 33.62 | 3.73 % | $ 2.23 B | USA |
 |
Concert Pharmaceuticals
CNCE
|
110 M | - | - | $ 401 M | USA |
 |
Akari Therapeutics, Plc
AKTX
|
17.3 M | $ 3.92 | 1.03 % | $ 264 B | Britain |
 |
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Celsion Corporation
CLSN
|
14.7 M | - | -6.63 % | $ 13.9 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
47.6 M | - | 3.16 % | $ 1.9 M | USA |